GlassScriptPhysician profile
Ayman Karkoutly
NPI 1477583052
$12,368.69
in general payments reported to CMS, 2019-2025
24 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,943 · 2020: $664 · 2021: $2,128 · 2022: $899 · 2023: $525 · 2024: $2,873 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Travel and Lodging: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.51 |
| Travel and Lodging | $1,633.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,448.83 | 2019-2020 | |
| Medtronic, INC. | $2,356.95 | 2021-2025 | Hawkone, Corevalve Evolut R, In.Pact Admiral |
| Penumbra, INC. | $2,285.76 | 2024 | Indigo System, Penumbra System |
| Novartis Pharmaceuticals Corporation | $788.04 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.27 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $556.76 | 2019-2025 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $260.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $242.92 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Boston Scientific Corporation | $209.01 | 2019-2025 | Latitude Communicator Power Supply |
| Janssen Pharmaceuticals, INC | $128.76 | 2019-2022 | |
| Celonova Biosciences, INC. | $123.95 | 2020 | |
| Amgen INC. | $99.82 | 2019-2021 | |
| Philips North America LLC | $50.15 | 2022-2025 | Philips Laser System |
| Arbor Pharmaceuticals, INC. | $41.98 | 2021 | |
| Abbott Laboratories | $39.20 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $30.25 | 2024-2025 | |
| Endologix LLC | $22.60 | 2020 | |
| Biotronik INC. | $19.85 | 2019 | |
| Esperion Therapeutics, INC. | $19.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.38 | 2022 | |
| Teleflex LLC | $14.84 | 2023 | Guideliner |
| Pfizer INC. | $14.02 | 2023 | |
| Gilead Sciences, INC. | $12.91 | 2019 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $10.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Karkoutly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.